oral, CNS-penetrant TRK(A-C) kinase inhibitor

Ph. II candidate for solid tumors (160 mg QD)

from literature starting point

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, CA

Chemical structure of molecule repotrectinib (TPX-0005)

The Turning Point Therapeutics oral, brain-penetrant ALK/ROS1/TRK kinase inhibitor, repotrectinib (TPX-0005), is a macrocyclic molecule with a small size intended to limit adverse interactions with resistance mutation hotspots near kinase active…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: